Eledon Pharmaceuticals, Inc. announced a Collaborative Research Agreement with Sernova Biotherapeutics on July 9, 2025. This partnership aims to evaluate Eledon’s immunosuppressive agent, tegoprubart, in Sernova’s ongoing Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial.
Tegoprubart will be used as an immunosuppressive agent in Cohort C of Sernova’s trial, which focuses on patients with Type 1 Diabetes. This collaboration expands the clinical development of tegoprubart into a new therapeutic setting for Type 1 Diabetes.
The agreement represents a strategic move to advance a potential functional cure for Type 1 Diabetes by combining Sernova's Cell Pouch technology with tegoprubart's immunomodulatory properties.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.